A porous biocomposite material including a polymer matrix having pores defined by several surfaces and collagen on the surface of the pores and the outer surfaces of the polymer matrix, the ratio, by weight, collagen to polymer matrix is from 20:80 to 40:60. The polymer matrix of the porous biocomposite material includes a copolymer which is prepared from a poly(ε-caprolactone) diol, a poly(lactide-co-glycolide) diol and a lysine diisocyanate (LDI). Also included are an implant which is a biodegradable, porous foam and with similar biomechanics to the normal meniscus, with tensile, compressive and tear strength, and preventing the pores from collapsing under condyle-tibia pressure. It serves as a scaffold for damaged meniscus repair or replacement, indicated for grade 3 or 4 terminal knee arthrosis, for the prevention of treatment, by cartilage regeneration, of advanced knee arthrosis, to avoid knee prostheses in young patients.

A substrate at least partially coated with an anti-fingerprint coating is prepared from a coating composition that includes: (a) an organic solvent; and (b) an alkoxysilane functional polymer having at least one ester linkage, at least one urethane linkage, and at least one alkoxysilane functional group. Further, the polymer is prepared from components including: (i) an active hydrogen functional compound having a hydroxyl group, amino group, thiol group, or a combination thereof; (ii) an intramolecular cyclic ester; and (iii) an isocyanate functional compound. The isocyanate functional compound (iii) has one or more alkoxysilane functional groups. Alkoxysilane functional polymers and coating compositions containing the same are also included.

The present disclosure provides copolymers useful in medical devices. For example, the disclosure provides copolymers comprising the polymerization product ester block, ether blocks and diisocyanates. In certain embodiments, the disclosure provides a medical copolymer for implantation comprising ester blocks and ether blocks, wherein: the ester blocks comprise a negative free energy transfer and the ether blocks comprise a positive free energy transfer, the ether and ester blocks are less than 1/10 the length of said copolymer, and, the blocks are distributed such that no domain of contiguous blocks possessing the same polarity of free energy transfer are less than ⅓ of the molecular weight of the copolymer. The disclosure further provides methods of making the aforementioned polymers, and medical devices comprising the polymers.

Described herein is a moisture-curing polyurethane hot-melt adhesive including at least 80% by weight, based on a total weight of the moisture-curing polyurethane hot-melt adhesive, of isocyanate-terminated prepolymer obtainable by mixing diisocyanate (a) with compounds having at least two isocyanate-reactive groups (b) and reacting the mixture to form the isocyanate-terminated prepolymer, where the compounds having at least two isocyanate-reactive groups (b) include at least one polylactide (b1) obtainable by reacting lactide with a linear difunctional starter molecule having 2 to 20 carbon atoms and the isocyanate content of the isocyanate-terminated prepolymer is 1 to 5% by weight. Also described herein is a process for producing such a moisture-curing polyurethane hot-melt adhesive and a method of using the moisture-curing polyurethane hot-melt adhesive in bonding of substrates.

Thermoplastic polyurethane (TPU) compositions, methods for producing TPU compositions, methods of using TPU compositions, and apparatuses produced therefrom are disclosed. Disclosed TPU compositions include a thermoplastic polyurethane polymer, a heat stabilizer, a flow agent, and a filler material. The filler may be a glass fiber. Disclosed TPU compositions have improved thermal stability and improved flow properties suitable for injection molding of articles of manufacture having a large plurality of fine openings or pores. Articles produced from the composition have superior thermal stability, abrasion resistance, and chemical resistance. Example articles include screening members for vibratory screening machines. Further embodiments include compositions without heat stabilizers, flow agents, and filler materials, and compositions in which two TPU materials having different harnesses are combined to generate a material with a pre-determined hardness. Injection molded screen elements having openings from 25 to 150 microns and open screening area from 10% to 35% are disclosed.

The invention is directed to a biodegradable, phase separated, thermoplastic multi-block copolymer, to a process for preparing a biodegradable, phase separated, thermoplastic multi-block copolymer, to the use of a biodegradable, semi-crystalline, phase separated, thermoplastic multi-block copolymer, and to a composition for the delivery of at least one biologically active compound to a host.

The biodegradable, phase separated, thermoplastic multi-block copolymer of the invention comprises at least one amorphous hydrolysable pre-polymer (A) segment and at least one semi-crystalline hydrolysable pre-polymer (B) segment, wherein said multi-block copolymer under physiological conditions has a T.sub.g of 37° C. or less and a T.sub.m of 50-110° C.; the segments are linked by a multifunctional chain extender; the segments are randomly distributed over the polymer chain; and the pre-polymer (B) segment comprises a X-Y-X tri-block, wherein Y is a polymerisation initiator, and X is a poly(p-dioxanone) segment with a block length expressed in p-dioxanone monomer units of 7 or more.

Provided herein are poly(ether ester) multi-block copolymers (PEE-MBCP). Also provided herein are injectable delivery systems or pharmaceutical compositions, comprising a PEE-MBCP provided herein, either alone or in combination with a binding protein, such as abicipar. Also provided herein are methods of using these injectable delivery systems or pharmaceutical compositions provided herein for the treatment of ocular disorders.

The invention is directed to biomedical polyurethanes. The invention is particularly directed to biomedical polyurethanes with improved biodegradability and to an improved preparation of the biomedical polyurethanes. In particular the present invention provides a biomedical polyurethane having the formula (A-B-C-B).sub.n, wherein A denotes a polyol, B denotes a diisocyanate moiety, C denotes a diol component and n denotes the number of recurring units, and wherein the B-C-B segment is bioresorbable.

A polymerizable composition for optical materials of the present invention includes a polymer (a) comprised of one or more compounds selected from compounds represented by the following General Formulas (1) to (4), a compound (b) of which light absorption characteristics vary by sensing changes in environment; and a polymerization reactive compound (c) (except for the polymer (a)). ##STR00001##

Process for increasingly producing D-Lactide and meso lactide by depolymerizing by back biting polylactide (PLA) said process which comprises: (i) Depolymerizing polylactide into its corresponding dimeric cyclic esters by heating the polylactide in the presence of a catalyst system comprising a catalyst and a co-catalyst in a reaction zone at temperature and pressure at which the polylactide is molten; (ii) Forming a vapor product stream from the reaction zone; (iii) Removing the vapor product stream and optionally condense it; (iv) Recovering, either together or separately meso-lactide, D-lactide and L-lactide.